Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedFeb 23, 2026
DataAggregated Company Financials
Companies151
  • 7D1.9%
  • 3M-6.4%
  • 1Y-7.7%
  • YTD-2.1%

Over the last 7 days, the Healthcare industry has risen 1.9%, driven by gains from BioArctic of 8.4%. In the past year, the industry is down 7.7%. Earnings are forecast to grow by 23% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 23 Feb 2026SEK 569.3bSEK 229.3b-SEK 1,647,883,826.1131.3x-345.5x2.5x
Wed, 21 Jan 2026SEK 587.6bSEK 230.1bSEK 3.7b41.1x160.2x2.6x
Fri, 19 Dec 2025SEK 574.0bSEK 230.7bSEK 3.6b41.1x157.4x2.5x
Sun, 16 Nov 2025SEK 603.6bSEK 230.5bSEK 2.9b44.4x205.9x2.6x
Tue, 14 Oct 2025SEK 599.2bSEK 227.1bSEK 6.7b43.1x89.7x2.6x
Thu, 11 Sep 2025SEK 610.7bSEK 227.0bSEK 6.6b44.7x92.4x2.7x
Sat, 09 Aug 2025SEK 605.3bSEK 226.8bSEK 6.8b45.4x88.5x2.7x
Mon, 07 Jul 2025SEK 629.2bSEK 227.1bSEK 6.0b44.6x104.5x2.8x
Wed, 04 Jun 2025SEK 605.0bSEK 226.4bSEK 5.8b43.1x103.5x2.7x
Fri, 02 May 2025SEK 593.2bSEK 223.8bSEK 4.9b37x121x2.7x
Sun, 30 Mar 2025SEK 571.6bSEK 220.9bSEK 5.4b36.2x105.8x2.6x
Tue, 25 Feb 2025SEK 587.5bSEK 206.1bSEK 4.4b36.9x133.5x2.9x
Thu, 23 Jan 2025SEK 589.1bSEK 202.6b-SEK 2,463,557,065.8641.7x-239.1x2.9x
Sat, 21 Dec 2024SEK 575.5bSEK 202.6b-SEK 2,503,131,958.0438.8x-229.9x2.8x
Mon, 18 Nov 2024SEK 509.8bSEK 199.9b-SEK 2,849,689,856.4537.4x-178.9x2.5x
Wed, 16 Oct 2024SEK 595.5bSEK 198.5b-SEK 2,314,588,459.1639.4x-257.3x3x
Fri, 13 Sep 2024SEK 617.3bSEK 200.2b-SEK 2,805,394,669.4540.9x-220x3.1x
Sun, 11 Aug 2024SEK 573.5bSEK 199.5b-SEK 2,394,284,457.5740.8x-239.5x2.9x
Tue, 09 Jul 2024SEK 570.9bSEK 195.9b-SEK 3,195,547,338.4438.5x-178.6x2.9x
Thu, 06 Jun 2024SEK 562.7bSEK 195.6b-SEK 2,827,643,502.4641.1x-199x2.9x
Sat, 04 May 2024SEK 537.6bSEK 196.5b-SEK 3,179,876,922.4334.8x-169x2.7x
Mon, 01 Apr 2024SEK 527.7bSEK 192.9b-SEK 3,674,506,154.3846x-143.6x2.7x
Wed, 28 Feb 2024SEK 506.0bSEK 191.8b-SEK 3,869,646,597.7449.1x-130.8x2.6x
Fri, 26 Jan 2024SEK 549.7bSEK 191.6b-SEK 899,735,716.0050.4x-610.9x2.9x
Sun, 24 Dec 2023SEK 534.3bSEK 191.0b-SEK 960,233,351.0047.8x-556.5x2.8x
Tue, 21 Nov 2023SEK 493.0bSEK 190.1b-SEK 1,226,384,668.0049.9x-402x2.6x
Thu, 19 Oct 2023SEK 427.4bSEK 185.1b-SEK 1,931,014,806.0031.9x-221.3x2.3x
Sat, 16 Sep 2023SEK 454.9bSEK 185.7b-SEK 2,024,682,673.0036.5x-224.7x2.4x
Mon, 14 Aug 2023SEK 474.6bSEK 184.3b-SEK 1,014,174,020.0041.7x-468x2.6x
Wed, 12 Jul 2023SEK 474.9bSEK 179.2b-SEK 787,767,930.0044.1x-602.9x2.7x
Fri, 09 Jun 2023SEK 510.2bSEK 179.0b-SEK 714,848,226.0041.5x-713.8x2.9x
Sun, 07 May 2023SEK 530.4bSEK 176.7b-SEK 667,620,231.0043x-794.5x3x
Tue, 04 Apr 2023SEK 489.1bSEK 172.5b-SEK 1,401,694,483.0035.5x-348.9x2.8x
Thu, 02 Mar 2023SEK 488.7bSEK 171.8b-SEK 1,138,677,080.0037.4x-429.2x2.8x
Price to Earnings Ratio

-429.2x


Total Market Cap: SEK 488.7bTotal Earnings: -SEK 1,138,677,080.00Total Revenue: SEK 171.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -169x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 10% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market1.86%
Healthcare1.89%
Life Sciences3.42%
Healthtech2.99%
Medical Equipment2.76%
Healthcare Services2.45%
Pharma1.06%
Biotech0.95%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 98.0x.
    • Analysts are expecting annual earnings growth of 20.4%, which is higher than its past year's earnings decline of 46.8% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 34% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Healthtech industry is expected to see its earnings grow by 16% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BIOA B BioArcticSEK 349.4010.9%
+SEK 3.0b		42.6%PE30.3x
SECT B SectraSEK 188.006.7%
+SEK 2.3b		-21.8%PE56x
MCOV B MedicoverSEK 217.504.1%
+SEK 1.3b		7.9%PE39.7x
AMBEA AmbeaSEK 124.507.4%
+SEK 706.1m		16.9%PE15.4x
ALIF B AddLifeSEK 143.804.1%
+SEK 694.6m		-13.6%PE31.3x

Latest News

ONCO
SEK 1.86
Oncopeptides
7D
-34.6%
1Y
19.2%
CAMX
SEK 532.50
Camurus
7D
-3.8%
1Y
-17.1%
CANTA
SEK 4.47
Cantargia
7D
-12.4%
1Y
204.1%
SOBI
SEK 402.40
Swedish Orphan Biovitrum
7D
-1.3%
1Y
28.8%

SOBI: Kidney And Sepsis Progress And Mixed Ratings Will Support Balanced Outlook

Narrative update The analyst price target for Swedish Orphan Biovitrum has been revised from about SEK 375.64 to SEK 416.45, with analysts citing updated assumptions on revenue growth, profit margins and future P/E, together with mixed recent rating changes, as the main drivers of this change. Analyst Commentary Recent rating changes show that analysts are split on Swedish Orphan Biovitrum, with one upgrade and one downgrade in quick succession.
SECT B
SEK 188.00
Sectra
7D
6.7%
1Y
-21.8%

SECT B: Expanding Cloud Imaging Footprint Will Drive Future Upside Potential

Analysts have maintained their SEK 245.0 price target for Sectra with only minor adjustments to assumptions, including a slightly higher discount rate and a marginally different future P/E. This reflects a largely steady view of the company’s valuation drivers.
BIOG B
SEK 107.40
BioGaia
7D
3.6%
1Y
-15.4%

BIOG B: Dividend Reset And Solid Margins Will Support Higher Future Earnings Multiple

Analysts have kept their SEK 140.0 price target for BioGaia broadly unchanged, citing slightly higher assumed discount rates and a modestly lower profit margin outlook. These factors are largely offset by stable long term growth and P/E expectations.
HNSA
SEK 32.22
Hansa Biopharma
7D
-19.5%
1Y
42.6%
BIOA B
SEK 349.40
BioArctic
7D
10.9%
1Y
42.6%
VIMIAN
SEK 26.66
Vimian Group
7D
-4.2%
1Y
-38.6%

VIMIAN: Reset Expectations Will Highlight Execution Under New CEO Appointment

Analysts have trimmed their fair value estimate and price target on Vimian Group to SEK 27 from SEK 37, reflecting updated assumptions around slightly higher growth, a lower profit margin profile and a higher expected P/E multiple, which together point to a more cautious risk return trade off. Analyst Commentary Bullish analysts looking at Vimian Group are focusing less on the headline downgrade and more on what the revised SEK 27 target implies for execution, valuation and growth expectations from here.
ASKER
SEK 63.78
Asker Healthcare Group
7D
-2.0%
1Y
n/a
AMBEA
SEK 124.50
Ambea
7D
7.4%
1Y
16.9%

Ambea (STO:AMBEA) Is Increasing Its Dividend To SEK2.65

Feb 15
Ambea (STO:AMBEA) Is Increasing Its Dividend To SEK2.65
DVYSR
SEK 95.40
Devyser Diagnostics
7D
-7.0%
1Y
-25.8%

Earnings Update: Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Feb 15
Earnings Update: Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
MCOV B
SEK 217.50
Medicover
7D
4.1%
1Y
7.9%
BONEX
SEK 183.10
Bonesupport Holding
7D
3.9%
1Y
-45.9%

Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?

Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
ALIF B
SEK 143.80
AddLife
7D
4.1%
1Y
-13.6%

Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings

Feb 12
Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings
GETI B
SEK 203.60
Getinge
7D
1.2%
1Y
-7.4%

GETI B: Higher P/E Expectations Will Outrun Softer Margins And Dividend Uplift

Analysts have adjusted their price target on Getinge from SEK165.00 to about SEK171.00, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Getinge AB (publ) has a proposed dividend of SEK 4.75 per share, compared with SEK 4.60 per share previously, subject to approval (Key Developments).